
- ONCOLOGY Vol 40, Issue 8
- Volume 40
- Issue 8
- Pages: 237
Advances in Hematologic Oncology: Reflections from the SOHO 2026 Annual Meeting
The 2026 SOHO Annual Meeting brought together clinicians, investigators, and translational scientists to discuss emerging data that are reshaping the diagnosis and management of patients with hematologic malignancies.
The field of hematologic oncology continues to evolve at an extraordinary pace, and the 2026 Annual Meeting of the Society of Hematologic Oncology (SOHO) provided an important forum for reviewing the rapidly changing therapeutic landscape. The meeting brought together clinicians, investigators, and translational scientists to discuss emerging data that are reshaping the diagnosis and management of patients with hematologic malignancies.
Several themes were particularly prominent throughout the meeting. First, the expanding role of immunotherapy and cellular therapies continues to transform the treatment of lymphoma, leukemia, and plasma-cell disorders. Bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies are increasingly being incorporated earlier in the treatment course, while ongoing studies are seeking to define optimal sequencing, combinations, and patient selection. The challenge now is not simply whether these therapies work, but how best to integrate them into routine practice while maximizing efficacy and minimizing toxicity. With earlier use of these agents in first or second line treatment, we need additional options for relapsed patients.
In B-cell lymphomas, treatment strategies continue to move toward increasingly individualized approaches. Data presented at SOHO 2026 highlighted advances in follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and other aggressive and indolent lymphomas. The growing number of effective targeted and immune-based therapies is creating opportunities for patients with relapsed or refractory disease, while also raising important questions about the appropriate timing of these treatments in earlier lines of therapy.
The meeting also underscored the remarkable progress in acute myeloid leukemia and myelodysplastic syndromes, particularly through molecularly targeted therapy. Increasing recognition of the biologic heterogeneity of these diseases is enabling treatment decisions to be guided by specific genetic and molecular abnormalities. At the same time, investigators continue to explore combinations of targeted agents with hypomethylating agents, venetoclax, chemotherapy, and cellular therapies in an effort to improve depth and durability of response.
In chronic lymphocytic leukemia and other mature B-cell neoplasms, the continued development of targeted agents is changing traditional treatment paradigms. Questions regarding treatment initiation, duration of therapy, resistance mechanisms, and sequencing of Bruton tyrosine kinase– and BCL2-directed therapies remain central to clinical decision-making. The field is increasingly moving away from a one-size-fits-all approach, toward strategies that incorporate disease biology, prior therapy, patient characteristics, and treatment goals.
Another important theme was the growing importance of minimal residual disease (MRD) as both a prognostic biomarker and a potential tool for treatment decisions. Across multiple hematologic malignancies, increasingly sensitive methods of disease detection are providing information beyond conventional response assessment. Whether MRD should routinely guide treatment duration or therapeutic escalation remains an area of active investigation.
Perhaps most importantly, the meeting demonstrated how quickly promising discoveries are moving from the laboratory into clinical practice. Advances in molecular profiling, artificial intelligence, novel drug development, immunotherapy, and cellular therapy are creating new possibilities for patients with diseases that historically had limited therapeutic options. At the same time, these advances bring practical challenges, including treatment-related toxicities, access to specialized therapies, financial considerations, and the need to determine which patients derive the greatest benefit from increasingly complex treatment strategies.
As hematologic oncology continues to advance, the importance of translating clinical trial results into practical, patient-centered care cannot be overstated. The data presented at SOHO 2026 provide both optimism and important questions for the years ahead. Our challenge as clinicians and investigators is to incorporate these advances thoughtfully, while continuing to identify areas in which existing therapies can be improved and where unmet clinical needs remain. With such a rapidly changing therapeutic landscape, we need to expedite the translation of basic information to clinical care rapidly.
Articles in this issue
Related to this article



